COVID-19 studies:  C19 studies: C19:  IvermectinIVM Vitamin DV.D HC QHC Q Vitamin CV.C ZincZn PXPX BHBH FPVFPV FLVFLV PVP-IPI CICI BLBL RDRD
HCQ study #169 of 280
10/24 Pre-Exposure Prophylaxis study (treated before exposed to the virus)
Goenka et al., SSRN, doi:10.2139/ssrn.3689618 (Preprint)
Seroprevalence of COVID-19 Amongst Health Care Workers in a Tertiary Care Hospital of a Metropolitan City from India
Source   PDF   Share   Tweet
Study of SARS-CoV-2-IgG antibodies in 1122 health care workers in India finding 87% lower positives for adequate HCQ prophylaxis, 1.3% HCQ versus 12.3% for no HCQ prophylaxis.
Adequate prophylaxis is defined as 400mg 1/wk for >6 weeks.

Goenka et al., 10/24/2020, retrospective, India, South Asia, preprint, 11 authors.
risk of IgG positive, 87.2% lower, RR 0.13, p = 0.03, treatment 1 of 77 (1.3%), control 115 of 885 (13.0%), adjusted per study, odds ratio converted to relative risk.

Effect extraction follows pre-specified rules prioritizing more serious outcomes. For an individual study the most serious outcome may have a smaller number of events and lower statistical signficance, however this provides the strongest evidence for the most serious outcomes when combining the results of many trials.
Details of all 280 studies    Meta analysis
Please send us corrections, updates, or comments. Vaccines and treatments are both extremely valuable and complementary. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation.